Food, Drugs, Healthcare, Life Sciences

On February 11, 2026, Samsung Bioepis, Co., Ltd ("Samsung") and Regeneron Pharmaceuticals, Inc. ("Regeneron")...

On January 11, 2026, the FDA issued two news releases putting forward reforms to the chemistry, manufacturing, and control requirements for cell and gene therapy products.

Last week, Congress enacted the Consolidated Appropriations Act of 2026. This legislation narrows the scope of the statutory protection for drugs for rare diseases and conditions under the Orphan Drug Act, 21 U.S. Code § 360cc.

Innovation in healthcare isn't just about technology—it's about reimagining how care is delivered at scale. Maneesh Goyal, Chief Operating Officer of Mayo Clinic Platform...

Duane Morris Takeaway: This week's episode features Duane Morris partners Jerry Maatman and Jennifer Riley and associates Ryan Garippo and Elizabeth Underwood with their discussion of the key trends and developments analyzed in the 2026 edition of the TCPA Class Action Review.

CMS is seeking input by March 30 on a proposed framework to promote U.S.-made PPE and essential medicines...

CMS is seeking input by March 30 on a proposed framework to promote U.S.-made PPE and essential medicines...

Administrative subpoenas have long been a powerful tool in the federal government's investigative arsenal.

Operating at full capacity thus far this year, the U.S. Food and Drug Administration ("FDA" or "agency") Office of Prescription Drug Promotion ("OPDP") has so far released seven untitled letters, reminding the industry that the agency continues to watch direct-to-consumer television ads closely.